Novartis acquires DTx Pharma to develop siRNA therapies

Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications

Helping Hand Foundation launches screening for glaucoma in Hyderabad

First of its kind screening for Glaucoma at grass root level over 10k screened already

PNB Housing and PVRI launch Pehel Eye Mitra to deliver free transport services to eye patients

Briefs: Link Pharma Chem and Zydus

USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad

Thermo Fisher Scientific to acquire CorEvitas for $912.5 million

Advances clinical research capabilities with leading regulatory grade registries platform

Dabur India expects 10%+ consolidated growth in Q1 FY24

However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.

Solara Active Pharma approves rights issue of Rs. 450 Cr

The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.

Adare Pharma divests Adare Biome to dsm-firmenich

The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x

Annovis’ Buntanetap in PD faces complex road ahead despite phase III progress, says GlobalData

The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023

Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide shows nearly 19% weight loss in people with obesity

Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite